News broadcaster Global Broadcast News debuts on BSE and NSE. The company had priced its IPO at the upper end of Rs 230 - Rs 250 price-band. The face value per share is Rs 10. The issue was subscribed heavily although FIIs were not allowed to participate. FIIs can buy the shares from the secondary market. The post-issue equity of the company is Rs 26.72 crore.
HCL Technologies reportedly plans to make a number of acquisitions in the United States and Europe over the next 18 months. The company is looking for potential targets in areas such as life sciences, aeronautics, semiconductor, auto and finance.
Ranbaxy Laboratories signed a deal to market Zenotech Laboratories generic biotech drug G-CSF in Europe. The deal will mark Ranbaxy's entry into biosimilars, or copy-cat versions of biotherapeutics. The global market for G-CSF, used to prevent infections caused by the reduction of white blood cells during chemotherapy, is about $1.6 billion. Ranbaxy, which has a strategic stake in Zenotech, already has a deal to sell 11 of the Hyderabad-based firm's cancer drugs in the United States.
Shilpa Medicare's board approved raising foreign portfolio limit to 75% of the share capital, the company said on Thursday.
Reliance Communications may see action following a newspaper report that Hutchison Telecommunications International had asked bidders for Indian mobile firm, Hutchisson Essar, to submit their offers by Friday (9 February 2007). Reliance Communications is in the fray to acquire Hutchisson Essar. Britain's Vodafone Group and the Hinduja group are also in the fray.
Deccan Cements approved setting up of a 1 million-tonne cement plant along with a captive power plant.
Jupiter Bioscience said on Wednesday it had received a significant order from Bachem, a global leader of peptides based in Switzerland. The business relationship is expected to be long-term, it added. The company has also entered into a confidentiality agreement with a big pharma company in Europe and in India for potential business collaboration in the peptide and chiral chemistry arenas. Jupiter Bioscience has also received commitments from a Nasdaq-listed company in the US for substantive business related to peptides.
Powered byCapital Market - Live News